Related Experiment Videos
Immunophenotyping is an independent factor for risk stratification in AML
1Department of Medicine III, University of Erlangen-Nuremberg, Erlangen, Germany. Roland.Repp@med3.imed.uni-erlangen.de
Cytometry. Part B, Clinical Cytometry
|April 30, 2003
Summary
Immunophenotyping aids in predicting acute myeloid leukemia (AML) patient outcomes. Specific cell surface markers identified through this method can stratify AML patients for better risk assessment and treatment planning.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Chromosomal abnormalities are key prognostic factors in acute myeloid leukemia (AML).
- Limited patients present with informative chromosomal abnormalities.
- The prognostic value of immunophenotyping in AML remains unclear.
Purpose of the Study:
- To investigate the prognostic significance of immunophenotyping in acute myeloid leukemia (AML).
- To determine if cell surface marker expression can predict patient survival and remission rates.
- To develop a prognostic score based on immunophenotypic markers for AML risk stratification.
Main Methods:
- Analysis of 783 newly diagnosed AML patients from German SHG-AML trials (1991, 1996).
- Utilized a 33-antibody panel for immunophenotyping.
- Correlated marker expression with overall survival, complete remission rate, and duration using multivariate analysis.
Main Results:
- Expression of CD9, CD11b, CD13, CD34, CD41 (negative) or CD15, CD33, CD38, CD64, MPO (positive) correlated with superior overall survival.
- Specific markers (CD13, CD34, CD41, CD64) improved complete remission rates, while others (CD9, CD11b, CD64) increased remission duration.
- CD9, CD13, CD34, and CD64 identified as independent prognostic factors for overall survival, forming a validated prognostic score.
Conclusions:
- Immunophenotyping provides independent prognostic significance in AML beyond diagnostic utility.
- Cell surface marker expression aids in risk stratification for AML patients.
- The developed prognostic score is effective, even in patients with normal karyotype or younger age.